LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of LPM6690176 Capsules in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and Bevacizumab in patients with RAS mutant metastatic colorectal cancer (mCRC), to observe the dose-limiting toxicity (DLT), and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D); Phase 2 is planned to preliminarily evaluate the efficacy of LPM6690176 capsule in combination with chemotherapy + Bev vs. chemotherapy + Bev in patients with previously untreated, RAS mutant mCRC.

Study Overview

• Status: Not yet recruiting
• Conditions: Metastatic Colorectal Cancer (mCRC)
• Intervention / Treatment: Drug: LPM6690176; Biological: Bevacizumab; Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)

• Study Type: Interventional
• Enrollment (Estimated): 99
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Lin Shen, Doctor; Phone Number: 0086-10-88196561; Email: doctorshenlin@sina.cn

Study Locations

• China
  • Beijing, China
    • Beijing Cancer Hospital
    • Contact: Lin Shen, Doctor; Phone Number: 0086-10-88196561; Email: doctorshenlin@sina.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Able to provide a signed informed consent;
2. Age ≥ 18 years and ≤ 75 years, both male and female;
3. Histologically confirmed metastatic colorectal cancer (CRC) with RAS mutation;
4. Prior therapies for colorectal cancer:

(1 ) For phase 1b patients: who have failed or intolerable to prior first-line therapy; (2) For phase 2 patients: who have not received prior systemic therapy for metastatic colorectal cancer.

5. At least one measurable lesion according to RECIST 1.1 criteria; 6. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1; 7. Life expectancy≥ 6 months; 8. Adequate bone marrow and organ function; 9. Negative pregnancy test for women of childbearing potential. patients of childbearing potential should take effective contraceptive measures during study drug treatment and until 6 months after initiation of investigational product.

Exclusion Criteria:

1. Patients with known microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR) who are suitable for immune checkpoint inhibitor therapy as assessed by the investigator;
2. Malignant tumors other than mCRC within 5 years before signing the informed consent;
3. Patients who did not recover from the AE of previous anti-tumor treatment to ≤ Grade 1;
4. Patients with body cavity effusion requiring local treatment or poorly controlled effusion;
5. Symptomatic brain metastasis, history of spinal cord compression or meningeal metastasis;
6. Underwent other therapeutic surgery other than diagnosis, biopsy, drainage, or expected to require major surgery during the study, or had unhealed wound, ulcer or fracture.
7. Current or previous uncontrolled concomitant non-gastrointestinal disease including, but not limited to myocardial infarction, unstable angina, coronary artery/peripheral artery bypass grafting, heart failure, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein thrombosis, serious arrhythmia, current uncontrolled hypertension, previous history of hypertensive crisis or hypertensive brain disease, tumor invasion into major blood vessels, interstitial lung disease, interstitial pneumonia, pulmonary interstitial fibrosis, reversible posterior leukoencephalopathy syndrome (RPLS), etc.;
8. Current or past presence of the gastrointestinal abnormalities, including but not limited to active peptic ulcer, clinically significant gastrointestinal abnormalities prior to informed consent, active colitis, long-term anticoagulant therapy, antiplatelet therapy, etc.;
9. Current or past significant risk of bleeding;
10. Use of prohibited medication or therapy within the specified time;
11. History of drug abuse or alcoholism;
12. Known hypersensitivity to any component of any investigational product;
13. Pregnant and lactating women;
14. Other conditions that may increase the risk of the study or interfere with study results, in the judgment of the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LPM6690176 24 mg/m2; LPM6690176 capsules administered 24 mg/m2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI+Bevacizumab	Drug: LPM6690176; LPM6690176 orally.; Biological: Bevacizumab; Bevacizumab intravenously; Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan); FOLFIRI intravenously
Experimental: LPM6690176 36 mg/m2; LPM6690176 capsules administered 36 mg/m2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI+Bevacizumab	Drug: LPM6690176; LPM6690176 orally.; Biological: Bevacizumab; Bevacizumab intravenously; Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan); FOLFIRI intravenously
Experimental: LPM6690176 42 mg/m2; LPM6690176 capsules administered 42 mg/m2 orally Day 1 through Day 5 and Day 15 through Day 19 of each 28-day cycle in combination with FOLFIRI+Bevacizumab	Drug: LPM6690176; LPM6690176 orally.; Biological: Bevacizumab; Bevacizumab intravenously; Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan); FOLFIRI intravenously

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Phase Ib: Dose-limiting toxicities (DLTs)	From the first dose of study drug treatment through Cycle 1 (28 days)
Phase Ib: Maximum tolerated dose (MTD)	From the first dose of study drug treatment through Cycle 1 (28 days)
Phase 1b: Recommended Phase 2 Dose (RP2D)	From the first dose of study drug treatment through Cycle 1 (28 days)
Phase 2: Overall response rate (ORR)	Approximately 2 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Overall survival (OS)	Approximately 2 years
Duration of response (DOR)	Approximately 2 years
Disease control rate (DCR)	Approximately 2 years
Progression-free survival (PFS)	Approximately 2 years
Phase 1b: Overall response rate (ORR)	Approximately 2 years
Maximum plasma concentration (Cmax)	From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days)
Time to maximum plasma concentration (Tmax)	From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days)
Area under the plasma concentration-time curve (AUC)	From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days)
Elimination half-life (t1/2)	From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 9 (Approximately 10 days, each cycle is 28 days)
Trough observed plasma concentration (Ctrough)	From Pre-dose of Cycle 1 Day 1 and up to Cycle 1 Day 19 (Approximately 20 days, each cycle is 28 days)
Adverse Events (AEs)	Approximately 2 years

Collaborators and Investigators

• Sponsor: Luye Pharma Group Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): March 31, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: December 9, 2025
• First Submitted That Met QC Criteria: February 2, 2026
• First Posted (Actual): February 6, 2026

Study Record Updates

• Last Update Posted (Actual): February 6, 2026
• Last Update Submitted That Met QC Criteria: February 2, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Intestinal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colonic Diseases; Colorectal Neoplasms; Amino Acids, Peptides, and Proteins; Proteins; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Camptothecin; Alkaloids; Enzymes and Coenzymes; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Pyrimidines; Formyltetrahydrofolates; Tetrahydrofolates; Folic Acid; Pterins; Pteridines; Uracil; Pyrimidinones; Coenzymes; Bevacizumab; Irinotecan; Fluorouracil; Leucovorin
• Other Study ID Numbers: LY01024/CT-CHN-102

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No